Plumbago zeylanica

Plumbago zeylanica (Ceylon Leadwort / Chitrak)

1. Identity

Botanical and Chemical Nomenclature

Plumbago zeylanica L. is commonly known as white chitraka and belongs to the family Plumbaginaceae. The generic name Plumbago is derived from the Latin words plumbum, meaning "lead," as this plant was reputed to cure lead poisoning and eye disease, and agere, meaning "to resemble." The specific epithet zeylanica means "from Sri Lanka," which was formerly called Ceylon. Other common names include Ceylon leadwort and white leadwort (English), and it is known as Chitrak in Ayurveda, Sheetraj Hindi in Unani, and Chittramoolam in Siddha. In Sanskrit it is referred to as Citraka. It is also called "Doctorbush" in some regions.

Botanical Description and Natural Distribution

Plumbago zeylanica is an evergreen perennial herbaceous plant featuring semi-woody stems 1–2 meters long that grow lax or climbing, with alternate thick fleshy oval-lance-elliptic leaves and white flowers arranged in terminal or axillary spikes 10–25 cm long. Native to tropical regions of eastern Asia including India and Malaysia, it has become widely naturalized across pantropical areas, particularly in open, disturbed habitats such as savannahs, forest edges, and coastal dunes up to 1,000 meters elevation. It is distributed as a weed throughout the tropical and subtropical countries of the world, and is a perennial sub-scandent shrub that grows throughout India, especially in Bengal, Uttar Pradesh, and South India. Botanical and ecological studies describe Plumbago zeylanica as a pantropical species, found throughout Asia and Africa, and also reported in parts of Central and South America.

Plant Parts Used and Common Preparations

The root and root bark of this herb are utilized in the preparation of varied Ayurvedic medicines. Roots of P. zeylanica are a rich source of the naphthoquinone plumbagin, and the demand for roots is increasing for plant-based medicines, health products, pharmaceuticals, and cosmetics in national and international markets. Common preparations include powder, decoction, tablets, and medicated oils, depending on the condition being treated. Leaves are applied topically as a paste for skin infections, sores, swelling, dysentery, and rheumatic pain, while flowers are used to aid digestion and seeds address muscular pain via decoction.

2. Traditional and Historical Use

Ayurveda (India)

Plumbago zeylanica has been used within the scope of Ayurvedic medicine, mentioned in the primary Ayurvedic text the Caraka Samhita, dating back thousands of years. Known as Chitrak, it is a classical Ayurvedic herb that has been used for the treatment of various health conditions since the time of the sage Charaka. It is classified as a powerful Rasayana Dravya, or rejuvenative herb. In Ayurveda, it is considered a rasayan.

Chitrak (Plumbago zeylanica) is a potent Ayurvedic herb known for its deep-penetrating and strong digestive (pachana) properties. It is used for managing conditions including Agnimandya (digestive fire disorders), where it enhances digestion and stimulates digestive fire (Agni), as well as for Kushta (leprosy and other skin disorders) due to its detoxifying properties, and Vata Vyadhi (diseases of Vata dosha) to alleviate chronic pain and colic.

In Indian Ayurvedic medicine, the roots of Plumbago zeylanica have been employed for over 2,500 years to treat digestive ailments including piles, indigestion, intestinal worms, colitis, ascites, and liver disorders, often prepared as a powder or decoction acting as a laxative, expectorant, appetizer, and tonic. The root bark is also used for rheumatism, scabies, chronic cough, bronchitis, menstrual irregularities, nervous disorders, obesity, and enlarged spleen or liver, with applications extending to abortifacient effects.

In the traditional system of medicine, it has been indicated for its significant protective role in enlarged liver and spleen. It is described as a bitter tonic and rejuvenator, well known for its use in chronic colds and cough.

Unani and Siddha Medicine

Plumbago zeylanica is an important constituent in various formulations used in Ayurveda, Unani, and Siddha. Commonly called Ceylon leadwort or Chitrak, it enjoys an important place among medicinal plants around the world for treatment of various diseases, and is held in high esteem in both Ayurveda and Unani. In the Unani system, it is known as Sheetraj Hindi, and in Siddha as Chittramoolam.

African Traditional Medicine

The root of Plumbago zeylanica is widely used by traditional Yoruba healers in Ibadan, Southwestern Nigeria, in the management and treatment of various infections and diseases. The plant is mainly harvested from the wild. It is commonly used in African and Asian folk medicine to treat a variety of diseases, including intestinal parasites, leprosy, rheumatism, skin diseases, diarrhea, ulcers, piles, and parasitic diseases.

Southeast Asia

Plumbago zeylanica is an important medicinal plant used in different parts of the world as traditional medicine for curing highly infectious diseases. It is widely accepted as ethnomedicine in India, Pakistan, Bangladesh, Sri Lanka, and Australia. It has innumerable traditional therapeutic applications in various diseases such as sores, ulcers, leprosy, cancer, diabetes, and tuberculosis. In traditional Burmese/Myanmar medicine, the leaf is used, with a sweet and sharp taste, for dissolving phlegm, while the root is used for gas, phlegm, and bile problems and in deworming and blood purification medicines.

Traditional Preparations and Uses Summary

Traditionally, P. zeylanica is used as a stimulant, digestant, expectorant, laxative, abortifacient, and in the treatment of muscular pain and rheumatic disease. The roots, leaves, and stem of the plant have been traditionally used to treat various disorders, including dysmenorrhea, leprosy, anemia, rheumatic pain, colds, coughs, and arthritis.

3. Key Constituents and Active Compounds

Primary Phytochemical: Plumbagin

Plumbagin is the major and most important phytochemical found in P. zeylanica. Chemically, plumbagin is 5-hydroxy-2-methyl-1,4-naphthoquinone, a quinone isolated from the roots of Plumbago zeylanica. Plumbagin (PLB) is an analogue of vitamin K3, with a chemical formula of C₁₁H₈O₃ and a molecular weight of 188.18 g/mol. It is a naturally occurring yellow pigment found in plants of the Plumbaginaceae, Droseraceae, Ancistrocladaceae, and Dioncophyllaceae families.

The roots and leaves of P. zeylanica contain plumbagin as a major component, constituting about 0.03% of dry weight of the roots. The leaves and root bark contain plumbagin. Plumbagin, zeylanone, and sitosterol have been identified in the flowers of the plant. The fruit confirmed the presence of plumbagin, glucopyranoside, and sitosterol.

Additional Naphthoquinones and Other Constituents

The root yields new pigments including 3-chloroplumbagin, 3,3-biplumbagin, binaphthoquinone identified as 3',6'-biplumbagin, and four other pigments identified as isozeylanone, zeylanone, elliptinone, and droserone. The isolation of plumbagin, droserone, isoshinanolone, and a new naphthalenone has been reported from the phenolic fraction of the light petrol extract of the roots.

Two plumbagic acid glucosides (3'-O-beta-glucopyranosyl plumbagic acid and 3'-O-beta-glucopyranosyl plumbagic acid methylester) along with five naphthoquinones (plumbagin, chitranone, maritinone, elliptinone, and isoshinanolone), and five coumarins (seselin, 5-methoxyseselin, suberosin, xanthyletin, and xanthoxyletin) have been isolated from the roots of Plumbago zeylanica. All coumarins were not previously found in this plant.

It is a potential source of diverse phytochemicals such as fatty acids, naphthoquinones, flavonoids, coumarins, alkaloids, steroids, terpenoids, glycosides, and others. The therapeutic uses of the plant have been attributed to the presence of bioactive compounds such as elliptinone, zeylanone, sitosterol, and plumbagin.

Biosynthesis and Physicochemical Properties

The basic skeleton of the naphthoquinone is produced by a polyketide synthase (PKS) using six acetyl units, with 3-methyl-1,8-naphthalene-diol as an intermediary product. Plumbagin is sparingly soluble in water; its clinical translation therefore requires formulations such as nanoemulsions. Since plumbagin is one of the pharmaceutically important phytoconstituents of P. zeylanica, its productivity is very low in the plant, which is insufficient to meet demand.

4. Mechanisms of Action

Anti-inflammatory and Immunomodulatory Mechanisms

Plumbagin has been reported to suppress the activation of NF-κB in tumor cells. NF-κB is a ubiquitous transcription factor that plays a central role in regulating diverse processes in leukocytes, including cellular proliferation, expression of immunoregulatory genes, and apoptosis during innate and adaptive immune responses. Inhibition of T cell proliferation by plumbagin is accompanied by a decrease in the levels of Con A-induced IL-2, IL-4, IL-6, and IFN-gamma cytokines, and similar immunosuppressive effects on cytokine levels have been seen in vivo.

Plumbagin significantly and dose-dependently suppresses paw edema in rats induced by carrageenan and various proinflammatory mediators, including histamine, serotonin, bradykinin, and prostaglandin E₂.

Anticancer Mechanisms

Plumbagin exerts anticancer activity via many molecular mechanisms, including targeting apoptosis, autophagy pathway, cell cycle arrest, antiangiogenesis pathway, anti-invasion, and antimetastasis pathway. Among these signaling pathways, the key regulatory genes regulated by plumbagin were NF-κB, STAT3, and AKT. Plumbagin also acts as a potent inducer of reactive oxygen species (ROS), suppressor of cellular glutathione, and novel proteasome inhibitor, causing DNA double-strand break by oxidative DNA base damage.

The cytotoxic effect of plumbagin-induced cell death is through the generation of reactive oxygen species (ROS) and subsequent induction of apoptosis. Plumbagin significantly inhibited growth of non-small cell lung cancer (NSCLC) cells, down-regulated expression of EGFR/Neu and its downstream signaling (Akt, NF-κB, Bcl-2, and survivin), up-regulated expression of p53 and p21(CIP1/WAF1) causing cell cycle arrest in G2/M-phase by down-regulating G2/M regulatory proteins (cyclinB1 and Cdc25B). Furthermore, it activated JNK/p38 signaling, leading to caspase-3 activation and induction of apoptosis.

Antidiabetic Mechanisms

Plumbagin significantly reduced blood glucose and significantly altered other biochemical parameters to near normal in streptozotocin (STZ)-induced diabetic rats. It increased the activity of hexokinase and decreased the activities of glucose-6-phosphatase and fructose-1,6-bisphosphatase significantly. Enhanced GLUT4 mRNA and protein expression were observed in diabetic rats after treatment with plumbagin, indicating that plumbagin enhanced GLUT4 translocation and contributed to glucose homeostasis.

5. Scientific Evidence by Area of Use

Important general note: No randomized controlled trials investigated on the human population were identified in systematic reviews of this plant's pharmacology as of 2021. The following evidence is therefore almost entirely preclinical (cell-based or animal studies), and strength of evidence for clinical benefit in humans is very weak across all areas.

5.1 Anticancer Activity

Cytotoxicity of isolated compounds to various tumor cell lines was evaluated, and plumbagin significantly suppressed growth of Raji, Calu-1, HeLa, and Wish tumor cell lines. Plumbagin induced cytotoxicity in human breast cancer cells (MDA-MB-231 and MCF-7) along with cell cycle arrest, DNA damage, apoptosis, and suppression of telomere and telomerase activity. In endocrine-resistant breast cancer cells (MCF-7/LCC2 and MCF7/LCC9), plumbagin inhibited their growth, invasion, and metastasis by suppressing Snail and altering expression of other epithelial-mesenchymal transition (EMT) markers.

Plumbagin is a natural naphthoquinone compound isolated from Plumbago zeylanica that has cytotoxic and antimigratory potential in many cancers. The cytotoxic mechanism in drug-resistant lung cancer has been poorly understood. One study examined the anticancer effect of plumbagin in both gefitinib-sensitive and resistant A549 lung cancer cells. The anticancer potential was demonstrated by MTT assay, and plumbagin showed cytotoxicity in both cell types, with IC₅₀ values of 3.2 μM and 4.5 μM, respectively.

In an experimental study, anticancer effect of ethanolic extract of Plumbago zeylanica leaves against the standard 5-Fluorouracil was investigated. The extract was administered orally to tumor-bearing mice at doses of 200 mg/kg and 400 mg/kg body weight for 14 consecutive days. Both doses evidentially reduced average body weight, decreased viable tumor cell count, and increased mice's lifetime for DAL treatment, with a reduction in blood flows, serum enzymes, and lipid profile close to normal values.

Plumbagin has been evaluated for its use in prostate cancer, and is being evaluated in phase I clinical trials for this indication. Study findings displayed that plumbagin lacks toxicity on normal colon cells and showed striking anti-survival effects on colon cancer cells.

Evidence strength: Predominantly in vitro (cell line) and animal studies. One phase I clinical trial in prostate cancer has been mentioned in scientific literature. No completed, published phase II/III human trials of P. zeylanica or plumbagin for cancer treatment have been identified in this review.

5.2 Antidiabetic Activity

Antidiabetic activity of an ethanolic extract of Plumbago zeylanica roots was reported in streptozotocin-induced diabetic rats at doses of 100–200 mg/kg for six weeks. Results showed a marked increase in hepatic hexokinase activity and reduction in hepatic glucose-6-phosphatase, serum acid phosphatase (ACP), alkaline phosphatase (ALP), and lactate dehydrogenase (LDH) levels.

A dedicated study evaluated the antidiabetic effects of plumbagin isolated from P. zeylanica roots and its effect on GLUT4 translocation in STZ-induced diabetic rats. Plumbagin (15 and 30 mg/kg body weight) was orally administered to STZ-induced diabetic rats for 28 days, and an oral glucose tolerance test was performed on the 21st day. Parameters measured included body weight, blood glucose, plasma insulin, total protein, urea, creatinine, liver glycogen, plasma enzymes (SGOT, SGPT, and ALP), and carbohydrate metabolism enzymes, as well as GLUT4 mRNA and protein expression in skeletal muscles. Plumbagin significantly reduced blood glucose and significantly altered all other biochemical parameters to near normal.

When administered to STZ-induced diabetic rats, plumbagin reduced blood glucose, increased activity of hexokinase, caused reduction in glucose-6-phosphatase and fructose-1,6-bisphosphatase, and raised GLUT4 mRNA and protein expressions, all contributing to alleviation of hyperglycemia.

Evidence strength: All studies cited are animal (rodent) models only. There is no published human clinical evidence for antidiabetic efficacy.

5.3 Anti-inflammatory and Analgesic Activity

In a study examining anti-inflammatory and analgesic effects of plumbagin orally administered in a range of dosages from 5 to 20 mg/kg in rats, the role of NF-κB and proinflammatory cytokines and mediators was examined. The results showed that plumbagin significantly and dose-dependently suppressed paw edema induced by carrageenan and various proinflammatory mediators including histamine, serotonin, bradykinin, and prostaglandin E₂.

Plumbagin completely inhibited Con A-induced IκB-alpha degradation and NF-κB activation. Furthermore, plumbagin prevented graft versus host disease-induced mortality in mice.

Evidence strength: Preclinical in vitro and animal studies only. No human clinical trials identified.

5.4 Antimicrobial Activity

Antimicrobial properties of the leaves extracts of the plant were studied against some known drugs. The in vitro antimicrobial activity and minimum inhibitory concentration (MIC) of the crude extract and the standard antibiotics were studied. Maximum inhibition was reported with leaves extracts as compared to standard antibiotics. In another study, methanolic extracts of the stem and leaves were investigated against six bacterial species and nine fungal species for antimicrobial studies.

The bioactive components present in P. zeylanica have demonstrated antimicrobial, antiviral, anticancer, antidiabetic, antioxidant, antifertility, antiobesity, antimalarial, and antisickling properties in preclinical studies.

Evidence strength: In vitro studies. Antimalarial activity, while demonstrated in vitro, has shown only weak in vivo activity in animal models.

5.5 Antimalarial Activity

The antimalarial activity of plumbagin has previously been demonstrated in vitro (good activity) and in vivo (weak activity). A pharmacokinetic study was conducted to investigate the profile following single oral dosing in order to explain inconsistency of results between the in vitro and in vivo antimalarial activities. Plumbagin has been reported to possess a wide spectrum of biological and pharmacological properties including activities against malaria, leishmania, and trypanosome parasites, as well as against virus, cancers, and bacteria.

Evidence strength: In vitro data is promising; in vivo animal data is weak, potentially due to pharmacokinetic limitations. No human clinical data.

5.6 Hepatoprotective Activity

Plumbago zeylanica showed a hepatoprotective effect against paracetamol-induced hepatotoxicity in male Wistar albino rats. Petroleum ether extract of the root of Plumbago zeylanica was investigated for hepatoprotective activity against paracetamol-induced liver damage. Various biochemical parameters were studied to evaluate the hepatoprotective activity of ethanolic extract, including serum total bilirubin, total protein, aspartate transaminase, alanine transaminase, alkaline phosphatase, lactate dehydrogenase, gamma-glutamyl transferase, total cholesterol, and serum triglycerides.

Evidence strength: Animal studies only. No human clinical trials identified. Notably, separate toxicity studies (see Section 7) found evidence of hepatotoxicity with sub-acute administration, creating a conflicting picture that requires further investigation.

5.7 Nephroprotective Activity

The protective effect of hydroalcoholic extract of P. zeylanica (HAPZ) in cisplatin-induced nephrotoxicity was analyzed in Swiss albino mice. Treatment with the higher dose (400 mg/kg) of HAPZ significantly reversed the adverse effect of cisplatin on kidney weight, serum urea, and creatinine, indicating a renoprotective effect. The antioxidant effect of the drug was evident from its significant effect on catalase, glutathione peroxidase, and lipid peroxidation activities.

Evidence strength: Single animal study only. No human clinical data.

5.8 Hypolipidemic Activity

The effect of ethanolic extract (50% v/v) of Plumbago zeylanica root alone and combined with vitamin E was studied in experimentally induced hyperlipidemic rabbits. There was a significant reduction in serum total cholesterol, LDL cholesterol, and triglyceride levels. Marked reduction was observed with the formulation of P. zeylanica and vitamin E. The total cholesterol/HDL and LDL/HDL cholesterol ratios were found significantly decreased (P < 0.05).

Evidence strength: Animal (rabbit) study. No human clinical data.

5.9 Memory-Enhancing Activity

Exteroceptive and interoceptive behavior models, including elevated plus maze, passive avoidance paradigm, and scopolamine-induced amnesia, were employed to evaluate the effect of Plumbago zeylanica roots on learning and memory in mice. Chloroform extract of P. zeylanica (100, 200, and 400 mg/kg orally) was administered for 10 successive days in separate groups. P. zeylanica at a dose of 200 mg/kg showed a promising memory-enhancing effect in mice, and the reversal of scopolamine-induced amnesia may be due to facilitation of cholinergic transmission in the mice brain.

Evidence strength: Animal studies only. No human clinical data.

5.10 Antifertility Activity

Antifertility activity of plumbagin was studied. When given orally at a dose of 1 mg/100 g body weight, plumbagin showed significant anti-implantation and abortifacient activity in albino rats without any teratogenic effect. The same dose of plumbagin had a significant anti-ovulatory effect in rabbits. Plumbagin administered at 10 mg/kg for 60 days caused selective testicular lesions in dogs. The wet weights of testes and epididymides were decreased, and there was a significant reduction in protein, RNA, and sialic acid concentration, whereas intratesticular cholesterol and acid/alkaline phosphatase were raised after drug treatment.

Evidence strength: Animal studies. This activity has significant overlap with reproductive toxicity concerns (see Section 7).

6. Body Systems and Health Areas of Association

Based on the totality of traditional use and preclinical evidence, Plumbago zeylanica has been associated with the following body systems and health areas:

• Digestive system: Treatment of piles, indigestion, intestinal worms, colitis, ascites, and liver disorders, with traditional use as a laxative, expectorant, appetizer, and tonic.
• Immune and inflammatory system: Antibacterial, antifungal, anti-inflammatory, antidiabetic, anticancer, antioxidant, hepatoprotective, cytotoxic, and wound-healing activities have been reported in various preclinical studies.
• Metabolic system: Antidiabetic, antiobesity, and hypolipidemic activities documented in animal models.
• Oncology: Evidence suggests that P. zeylanica has potential in the treatment of various metabolic diseases, hepatotoxicity, diabetes, inflammation, cancer, and other disease complications.
• Reproductive system: Traditional use as an abortifacient and emmenagogue, and documented antifertility effects in animal research.
• Nervous system: In the Ayurvedic system, the roots and constituents are credited with potential cardiotonic, neuroprotective, and CNS-stimulating properties.
• Skin: Used as a traditional medicine in Ethiopia and elsewhere for skin diseases.
• Renal system: Nephroprotective effects in cisplatin-induced nephrotoxicity models.
• Musculoskeletal system: Traditional use for rheumatic pain, arthritis, and muscular complaints.

7. Dosage Forms and Reported Dosages

The following dosages appear specifically in scientific studies or traditional medicine descriptions; these are not clinical recommendations:

• In streptozotocin-induced diabetic rats, plumbagin was orally administered at doses of 15 and 30 mg/kg body weight for 28 days.
• Antidiabetic activity of ethanolic extract of P. zeylanica roots was studied in STZ-induced diabetic rats at doses of 100–200 mg/kg for six weeks.
• Anti-inflammatory and analgesic effects of plumbagin were investigated with oral administration in rats at a range of dosages from 5 to 20 mg/kg.
• In anticancer studies, ethanolic leaf extract was administered orally to tumor-bearing mice at doses of 200 mg/kg and 400 mg/kg body weight for 14 consecutive days.
• For genoprotective effects, alcoholic root extract of P. zeylanica was administered at 250 and 500 mg/kg body weight orally for 5 days in mice.
• In nephroprotective studies, the higher dose of 400 mg/kg of hydroalcoholic extract was required to significantly reverse cisplatin-induced adverse effects in mice.
• In antifertility studies in albino rats, plumbagin was given orally at 1 mg/100 g body weight.
• Plumbagin administered at 10 mg/kg for 60 days caused testicular lesions in dogs.
• Traditional Ayurvedic use: Typical dosage in traditional use ranges from 250 mg to 1 g of Chitrak powder per day.

8. Safety, Toxicity, and Drug Interactions

General Toxicity Profile

Plumbagin has significant pharmacokinetic disadvantages, including a short half-life and limited solubility, and represents a potential safety risk due to its cytotoxic effects on healthy cells and its genotoxic effects. Plumbagin has a very short half-life; it is structurally identical to vitamin K and has a limited oral bioavailability, mild toxicity, and low water solubility.

Acute Toxicity

Acute toxicity studies in mice and rats showed plumbagin to be toxic, with an LD₅₀ value of 4 mg/100 g body weight in mice and 6.5 mg/100 g in rats. One series of preclinical studies showed a good margin of safety as determined by acute toxicity studies in albino rats and albino rabbits, as well as by the absence of adverse effects on haematological and biochemical parameters in albino rabbit up to 60 days of administration. These contrasting outcomes likely reflect differences in dose, extract type, and route of administration.

Organ Toxicity: Liver and Kidney

A study demonstrated that liver and kidney are the primary organs adversely affected following sub-acute administration of P. zeylanica root extract in rats. Studies with related species (Plumbago indica) further corroborate hepatotoxic potential: imbalance of the antioxidative system by plumbagin and Plumbago indica extract induces hepatotoxicity in mice. A study examined the effects of plumbagin (1, 5, and 15 mg/kg/day) or PI extract (20, 200, and 1,000 mg/kg/day) administered intragastrically for 14 days, examining hepatic histomorphology.

Dermal Toxicity

Skin irritation testing on rabbits showed Plumbago zeylanica extract to be a moderate irritant, with a primary irritation index of 2.00. Sensitization testing on mice by the Mouse Ear Swelling Test method revealed the extract to be a non-sensitizer in a dose range of 4–10 mg/ml. Plumbagin is also noted to be a powerful irritant.

Reproductive and Developmental Toxicity

Some workers reported significant anti-implantation and abortifacient activity in albino rats without any teratogenic effect of plumbagin at doses of 1 mg/100 g. The roots of Plumbago zeylanica have been reported to be a powerful poison when given orally or applied to the ostium uteri, causing abortion. Plumbagin at 10 mg/kg administered for 60 days caused selective testicular lesions in dogs, with decreased wet weights of testes and epididymides, and a significant reduction in protein, RNA, and sialic acid concentration.

Bioavailability Limitations

In rodent models, plumbagin has been reported to have a bioavailability of less than 40% and is highly lipophilic, meaning a portion of the compound tends to concentrate in cell membranes as opposed to remaining in circulation. Translation of plumbagin into clinical application is made difficult by its poor water solubility. An ex vivo permeation study revealed that a self-nanoemulsifying drug delivery system had almost twice the intestinal permeability as that of pure plumbagin. Novel nanoemulsion formulations based on Capryol 90 and oleic acid have shown high drug loading capacity.

Cytochrome P450 Interactions

The propensity of plumbagin to modulate the mRNA expression and activities of hepatic drug-metabolizing enzyme cytochrome P450 (CYP450), specifically CYP1A2 and CYP3A11, was investigated using microsomes prepared from mouse livers. This finding suggests a potential for pharmacokinetic drug-drug interactions, particularly with medications metabolized by these enzymes, though the clinical magnitude of such interactions has not been characterized in human subjects.

Conservation Concern

The growing demand for the roots of P. zeylanica is creating heavy pressure on the natural plant populations in the wild due to over-harvesting. The indiscriminate collection of roots and non-cultivation of the plant has many implications for biodiversity, and the plant is becoming scarce due to increasing demand for its use in ethnobotanical practice.

Overall Evidence Assessment

Ongoing research aims to better understand the mechanisms underlying the actions of plumbagin, optimize its distribution and formulation, and assess its efficacy and safety in clinical trials. Plumbagin is a bioactive compound with several possible therapeutic uses; however, further studies are required to completely understand its advantages and disadvantages in clinical settings. Plumbagin and its derivatives have high therapeutic potential, particularly in oncology and antibacterial applications. However, issues such as bioavailability and toxicity must be addressed. Advances in drug delivery technologies, chemical modifications, and combination therapy are being explored as approaches for increasing therapeutic viability. Further clinical investigations are needed to completely comprehend the therapeutic potential and guarantee human safety.

References

• Yin Z, et al. "Anticancer Effects and Mechanisms of Action of Plumbagin: Review of Research Advances." BioMed Research International, 2020. PMC7725562.
• Nair S, et al. "Anticancer mechanism of plumbagin, a natural compound, on non-small cell lung cancer cells." PubMed, 2008. PMID: 18507021.
• Checker R, et al. "Plumbagin induces reactive oxygen species, which mediate apoptosis in human cervical cancer cells." PubMed, 2004. PMID: 15264212.
• "Anti-inflammatory and analgesic effect of plumbagin through inhibition of nuclear factor-κB activation." PubMed, 2010. PMID: 20858709.
• "Anti-inflammatory effects of plumbagin are mediated by inhibition of NF-kappaB activation in lymphocytes." International Immunopharmacology, 2009. PMID: 19374955.
• Lin LC, et al. "Cytotoxic naphthoquinones and plumbagic acid glucosides from Plumbago zeylanica." PubMed, 2003. PMID: 12560036.
• Sunil C, et al. "Antidiabetic effect of plumbagin isolated from Plumbago zeylanica L. root and its effect on GLUT4 translocation in streptozotocin-induced diabetic rats." Food and Chemical Toxicology, 2012. PMID: 22960630.
• Koepfli K, et al. "Pharmacokinetics, toxicity, and cytochrome P450 modulatory activity of plumbagin." BMC Pharmacology and Toxicology, 2016. PMC5108082.
• "Comparative toxicity profiles of Plumbago zeylanica L. root petroleum ether, acetone and hydroalcoholic extracts in Wistar rats." PMC, 2016. PMC4895762.
• "Phytochemical evaluation of roots of Plumbago zeylanica L. and assessment of its potential as a nephroprotective agent." PMC, 2017. PMC5415120.
• Dhivya S, et al. "Phytochemistry and pharmacological studies of Plumbago zeylanica L.: a medicinal plant review." Clinical Phytoscience, 2021.
• Thekkumkara SN, et al. "Different Derivatives of Plumbagin Analogue: Bioavailability and Their Toxicity Studies." Food Science & Nutrition / PMC, 2025. PMC12365397.
• "Current development in novel drug delivery systems of bioactive molecule plumbagin." Artificial Cells, Nanomedicine, and Biotechnology, 2018.
• "Plumbago zeylanica L.: A Mini Review." ResearchGate, 2012.
• "Pharmacological Profiles of Ethno-Medicinal Plant: Plumbago zeylanica L. — A Review." International Journal of Pharmaceutical Sciences Review and Research, 2014.
• "Plumbago zeylanica: A Phytopharmacological Review." International Journal of Pharmaceutical Sciences and Research.
• "Plumbago zeylanica." PlantZAfrica — SANBI (South African National Biodiversity Institute), 2020.
• "Pharmacokinetics, toxicity, and cytochrome P450 modulatory activity of plumbagin." BMC Pharmacology and Toxicology, 2016.
• Bloch K, et al. "Natural Compounds from Plumbago zeylanica as Complementary and Alternative Medicine." Handbook of Oxidative Stress in Cancer: Therapeutic Aspects, Springer, 2022.
• "Toxicity studies on dermal application of plant extract of Plumbago zeylanica used in Ethiopian traditional medicine." Academia.edu.